New head-to-head data proving biosimilar versions of some of the world's bestselling rheumatoid arthritis (RA) therapies are as safe and effective as their branded counterparts are being presented by Merck & Co. Inc., its partner Samsung Bioepis Co. Ltd. and competitors at the European League Against Rheumatism Annual Congress this week.